Description
Transferrin Receptor Protein-1 (TFRC) HEK293 Recombinant Cell Line | 78308 | Gentaur US, UK & Europe Disrtribition
Category: Neuroscience/Cell Line
Application: 1. Useful for screening or performing binding assays of antibodies designed against human Transferrin Receptor-1 in a cellular context.
2. Study of endocytosis kinetics on transferrins and their derivatives in cellular uptake assays for the development of next generation culture media formulations.
3. Preliminary assessment of transferrin receptor-targeted nanoparticle complexes (immunoliposomes) designed to deliver therapeutic payloads across the blood brain barrier (BBB) via transcytosis.
Background: Transferrin Receptor Protein-1 (TFRC) is a cell surface receptor that binds ferric-iron-loaded transferrin in the bloodstream at high affinity to facilitate iron uptake into cells. TFRC is therefore an integral component of the body's iron supply chain and general homeostasis. Intracellular iron levels, hypoxia and CRE signaling regulate TFRC transcription. In addition, TFRC is upregulated in correlation with tumor-progressive stages of multiple forms of cancer. At the cellular level iron surplus results in oxygen radical formation and cellular dysfunction, while iron deficiency can cause rapid cell death. Deregulated iron levels are therefore correlated with multiple disease states including Parkinson's Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington's Disease, Multiple Sclerosis (MS), and tumorigenesis. Equally important are potential therapeutic uses of TFRC. As TFRC is upregulated on the surface of tumor cells, it has been targeted to inhibit adult T-cell leukemia/lymphoma. Additionally, TFRC has found important utility in treatments of neurological diseases. Drug discovery in the central nervous system (CNS) space has historically been challenged by limited access of therapeutics across the blood brain barrier (BBB). As TFRC is highly expressed on the surface of brain capillary endothelial cells within the BBB, drug delivery strategies are being developed to leverage transcytosis of TFRC-bound entities from the bloodstream to the CNS (i.e. receptor mediated transport, or RMT). Current approaches include PEGylated liposomes coated with the TFRC ligand transferrin, as well as anti-TFRC antibodies linked to nanoparticles (immunoliposomes) carrying a therapeutic payload.
Description: Recombinant clonal HEK293 stable cell line constitutively expressing full length human Transferrin Receptor Protein-1 (TFRC and TFR1, also known as human CD71 protein, GenBank accession #NM_001128148). The surface expression of TFRC was confirmed by flow cytometry.
Product Type: Cell Line
Shippement Condition: -80°C
